medigraphic.com
ISSN 0028-3851 (Print)

2023, Number 2

<< Back Next >>

Rev Neurol Neurocir Psiquiat 2023; 51 (2)

Alemtuzumab

Cerino PVM

Language: Spanish
References: 18
Page: 77-79
PDF size: 104.30 Kb.





REFERENCES

  1. Syed YY. Alemtuzumab: a review in relapsing remitting multiple sclerosis. Drugs. 2021; 81 (1): 157-168.

  2. Freedman MS, Kaplan JM, Markovic-Plese S. Insights into the mechanisms of the therapeutic efficacy of alemtuzumab in multiple sclerosis. J Clin Cell Immunol. 2013; 4 (4): 1000152.

  3. Zhang X, Tao Y, Chopra M, Ahn M, Marcus KL, Choudhary N, et al. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis. J Immunol. 2013; 191 (12): 5867-5874.

  4. De Mercanti S, Rolla S, Cucci A, Bardina V, Cocco E, Vladic A, et al. Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months. Neurol Neuroimmunol Neuroinflamm. 2016; 3 (1): e194.

  5. Aguilar-Juárez PA, Castillo-Lara RA, Ceballos-Godina M, Colorado-Ochoa HJ, Espinosa-Zacarías JP, Flores-Ramírez FG et al. Consenso para el diagnóstico y tratamiento de la esclerosis múltiple en pacientes del ISSSTE. Med Interna Méx. 2019; 35 (5): 732-771.

  6. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012; 380 (9856): 1819-1828.

  7. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012; 380 (9856): 1829-1839.

  8. CAMMS223 Trial Investigators; Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008; 359 (17): 1786-1801.

  9. Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018; 90 (17): 777-788.

  10. Berger T, Elovaara I, Fredrikson S, McGuigan C, Moiola L, Myhr KM et al. Alemtuzumab use in clinical practice: recommendations from european multiple sclerosis experts. CNS Drugs. 2017; 31 (1): 33-50.

  11. Meca-Lallana JE, Fernández-Prada M, García Vázquez E, Moreno Guillén S, Otero Romero S, Rus Hidalgo M et al. Consensus statement on the use of alemtuzumab in daily clinical practice in Spain. Neurologia (Engl Ed). 2020: S0213-4853(19)30146-X.

  12. Steingo B, Al Malik Y, Bass AD, Berkovich R, Carraro M, Fernández Ó et al. Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. J Neurol. 2020; 267 (11): 3343-3353.

  13. Ziemssen T, Bass AD, Berkovich R, Comi G, Eichau S, Hobart J et al. Efficacy and safety of alemtuzumab through 9 years of follow-up in patients with highly active disease: post hoc analysis of CARE-MS I and II patients in the TOPAZ extension study. CNS Drugs. 2020; 34 (9): 973-988.

  14. Freeman L, Longbrake EE, Coyle PK, Hendin B, Vollmer T. High-efficacy therapies for treatment-naïve individuals with relapsing-remitting multiple sclerosis. CNS Drugs. 2022; 36 (12): 1285-1299.

  15. Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E et al. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. Neurology. 2017; 89 (11): 1117-1126.

  16. Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018; 24 (2): 96-120.

  17. Valeria RC, Roberta L, Francesco S, Marcello M, Antonio C, Vincenzo BM. Pregnancy outcomes in alemtuzumab treated women with multiple sclerosis: a case series. Neurol Sci. 2021; 42 (8): 3427-3430.

  18. Kashani N, Kelland EE, Vajdi B, Anderson LM, Gilmore W, Lund BT. Immune regulatory cell bias following alemtuzumab treatment in relapsing-remitting multiple sclerosis. Front Immunol. 2021; 12: 706278.




2020     |     www.medigraphic.com